Switching from long-term androgen treatment to Takhzyro (lanadelumab) successfully prevented swelling attacks and reduced cardiovascular risk in a man with hereditary angioedema (HAE) type 1, according to a report from Italy. The man had undergone two kidney transplants and was on immunosuppressant medications for several years. According to…
A European Medicines Agency (EMA) committee has recommended that the antibody-based therapy garadacimab be approved as a once-monthly preventive treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE) ages 12 and older. The positive opinion from the EMA’s Committee for Medicinal Products…
Treatment with navenibart, or STAR-0215, safely reduced the rate of monthly swelling attacks by 90% to 95% in people with hereditary angioedema (HAE) when the therapy was given once or twice over six months, data from the completed Phase 1/2 ALPHA-STAR clinical trial shows.
There are notable differences between hereditary angioedema with normal C1-inhibitor function (HAE nC1-INH) and idiopathic angioedema of unknown etiology (AE-UNK), even though they share many features, a real-world Canadian study indicates. Some of the differences include the time to reach a diagnosis, attack triggers and characteristics, and treatment…
Theratechnologies said it will ask Health Canada next year to approve donidalorsen, an experimental injection therapy designed to reduce the risk of swelling attacks in people with hereditary angioedema (HAE). The company agreed to acquire exclusive rights to commercialize the treatment in the country. Donidalorsen, originally developed…
Stroke patients treated with alteplase, a medication used to dissolve blood clots, are at an increased risk of developing angioedema, a retrospective study has found. Being female, using ACE or angiotensin-converting enzyme inhibitors, and having high blood pressure were all identified as “significant risk factors for angioedema among alteplase-treated…
Rare connective tissue diseases are more common among people with hereditary angioedema (HAE) than in the general population, according to the results of a new Italian study the researchers say is the first to seek to better understand disease prevalence among HAE patients. Among the diseases investigated — which…
Orladeyo (berotralstat), an oral therapy designed to reduce or prevent hereditary angioedema (HAE) attacks, is now available in Ireland. The Irish Health Services Executive (HSE) recommended Orladeyo as a prophylactic, or preventive, treatment for HAE in adults and adolescents, ages 12 and older. Biocryst Pharmaceuticals, the company marketing…
Astria Therapeutics is planning the launch of a Phase 3 clinical trial in early 2025 to test different dosing schedules of navenibart, its preventive therapy for hereditary angioedema (HAE). The goal, according to Astria, is to provide flexibility for patients, with different dosing options, should the treatment candidate…
DRI Healthcare Trust, an investment firm, has acquired rights to royalty interest in sebetralstat, an on-demand treatment for hereditary angioedema (HAE) that’s being considered for approval in several countries, including the U.S. For Kalvista Pharmaceuticals, the therapy’s developer, the deal could be worth more than $175 million,…
Get regular updates to your inbox.